Literature DB >> 22105598

Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding.

A Seshire1, T Rößiger, M Frech, S Beez, H Hagemeyer, E Puccetti.   

Abstract

The homeostasis of hematopoiesis in the bone marrow is governed by a small number of key transcription factors, including PU.1, GATA-1 and c/EBPα. PU.1, a member of the E-twenty-six family of transcription factors, is indispensable for normal hematopoiesis. Inactivation of PU.1 induces acute leukemia in mice. Recent data suggest that the leukemia-associated fusion protein pro-myelocytic leukemia/retinoic acid receptor alpha (PML/RARα) inhibits PU.1, but the mechanism mediating this inhibition is unclear. Here, we investigated the mechanisms by which the fusion proteins PML/RARα and pro-myelocytic leukemia zinc finger/RARα (PLZF/RARα) (X-RARα) interfere with the function of PU.1. We found that X-RARα proteins functionally inactivate PU.1 by reducing its promoter-binding capacity, resulting in a reduction in PU.1-dependent transcriptional transactivation. In fact, X-RARα proteins directly interact with PU.1, leading to both the sequestration of PU.1 from its target promoters and a reduction in its serine phosphorylation, which is crucial for its promoter binding and transcriptional activity. We found that the functional inactivation of PU.1 could be overcome by the forced overexpression of PU.1 in PML/RARα- or PLZF/RARα-positive murine hematopoietic progenitor cells; evidently, this overexpression rescued the leukemic differentiation block induced by X-RARα proteins. Our data thus provide strong evidence that X-RARα proteins functionally inhibit PU.1, shedding light on the mechanism by which X-RARα proteins induce leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22105598     DOI: 10.1038/leu.2011.331

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  Architecture of a lymphomyeloid developmental switch controlled by PU.1, Notch and Gata3.

Authors:  Marissa Morales Del Real; Ellen V Rothenberg
Journal:  Development       Date:  2013-03       Impact factor: 6.868

Review 2.  The role of zinc and its compounds in leukemia.

Authors:  Alexey P Orlov; Marina A Orlova; Tatiana P Trofimova; Stepan N Kalmykov; Dmitry A Kuznetsov
Journal:  J Biol Inorg Chem       Date:  2018-02-28       Impact factor: 3.358

3.  PU.1 affects proliferation of the human acute myeloid leukemia U937 cell line by directly regulating MEIS1.

Authors:  Jing Zhou; Xiaofeng Zhang; Yuhua Wang; Yinghui Guan
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

4.  Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis.

Authors:  Steven D Rhodes; Hao Yang; Ruizhi Dong; Keshav Menon; Yongzheng He; Zhaomin Li; Shi Chen; Karl W Staser; Li Jiang; Xiaohua Wu; Xianlin Yang; Xianghong Peng; Khalid S Mohammad; Theresa A Guise; Mingjiang Xu; Feng-Chun Yang
Journal:  J Bone Miner Res       Date:  2015-05-21       Impact factor: 6.741

5.  Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes.

Authors:  C-E Chong; P Venugopal; P H Stokes; Y K Lee; P J Brautigan; D T O Yeung; M Babic; G A Engler; S W Lane; M Klingler-Hoffmann; J M Matthews; R J D'Andrea; A L Brown; C N Hahn; H S Scott
Journal:  Leukemia       Date:  2017-06-23       Impact factor: 11.528

6.  Targeting the acute promyelocytic leukemia-associated fusion proteins PML/RARα and PLZF/RARα with interfering peptides.

Authors:  Sabine Beez; Philipp Demmer; Elena Puccetti
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

7.  PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity.

Authors:  Nélida Inés Noguera; Maria Liliana Piredda; Riccardo Taulli; Gianfranco Catalano; Giulia Angelini; Girish Gaur; Clara Nervi; Maria Teresa Voso; Andrea Lunardi; Pier Paolo Pandolfi; Francesco Lo-Coco
Journal:  Oncotarget       Date:  2016-10-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.